IO Biotech Revenue and Competitors
Estimated Revenue & Valuation
- IO Biotech's estimated annual revenue is currently $7.4M per year.
- IO Biotech's estimated revenue per employee is $80,000
- IO Biotech's current valuation is $219M. (January 2022)
Employee Data
- IO Biotech has 93 Employees.
- IO Biotech grew their employee count by 15% last year.
IO Biotech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.5M | 27 | -7% | N/A | N/A |
#2 | $4096.4M | 10837 | 2% | N/A | N/A |
What Is IO Biotech?
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
keywords:N/A
N/A
Total Funding
93
Number of Employees
$7.4M
Revenue (est)
15%
Employee Growth %
$219M
Valuation
N/A
Accelerator
IO Biotech News
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology...
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
Other Companies in Copenhagen
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $25.1M | 93 | 0% | N/A |
#2 | $23.6M | 94 | 25% | N/A |
#3 | $13.6M | 94 | 65% | N/A |
#4 | $16.9M | 94 | 34% | N/A |
#5 | $13.8M | 95 | 40% | N/A |